GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » FCF Margin %

BioVaxys Technology (BioVaxys Technology) FCF Margin % : 0.00% (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioVaxys Technology's Free Cash Flow for the three months ended in Jul. 2023 was $-0.02 Mil. BioVaxys Technology's Revenue for the three months ended in Jul. 2023 was $0.00 Mil. Therefore, BioVaxys Technology's FCF Margin % for the quarter that ended in Jul. 2023 was 0.00%.

As of today, BioVaxys Technology's current FCF Yield % is -11.78%.

The historical rank and industry rank for BioVaxys Technology's FCF Margin % or its related term are showing as below:


BVAXF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -139.2
* Ranked among companies with meaningful FCF Margin % only.


BioVaxys Technology FCF Margin % Historical Data

The historical data trend for BioVaxys Technology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology FCF Margin % Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
FCF Margin %
- - - - -

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioVaxys Technology's FCF Margin %

For the Biotechnology subindustry, BioVaxys Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's FCF Margin % falls into.



BioVaxys Technology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioVaxys Technology's FCF Margin for the fiscal year that ended in Oct. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Oct. 2022 )/Revenue (A: Oct. 2022 )
=-1.151/0
= %

BioVaxys Technology's FCF Margin for the quarter that ended in Jul. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jul. 2023 )/Revenue (Q: Jul. 2023 )
=-0.018/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

BioVaxys Technology (BioVaxys Technology) Headlines

From GuruFocus